Narrow Results By
Authorizing cannabis for medical purposes
https://policybase.cma.ca/link/policy11514
- Last Reviewed
- 2020-02-29
- Date
- 2015-02-28
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
POLICY
Authorizing Cannabis for Medical Purposes
The legalization of cannabis for recreational purposes came into effect with the Cannabis Act
in October 2018, and patients continue to have access to cannabis for therapeutic purposes.
The Cannabis Regulations
1
have replaced the Access to
Bill C-45: the Cannabis Act
https://policybase.cma.ca/link/policy13723
- Date
- 2017-08-18
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
CMA Submission:
Bill C-45: The Cannabis Act
Submission to the House of Commons Standing Committee
on Health
August 18, 2017
The Canadian Medical Association (CMA) is the national
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861
- Date
- 2018-04-18
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
CMA Submission:
Bill C-45: The Cannabis Act
Submission to the Senate Standing Committee, Social
Affairs, Science &Technology
April 18th, 2018
Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726
- Date
- 2017-05-26
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
Canada’s
Lower-Risk
Cannabis Use
Guidelines (LRCUG)
Recommendations
• Cannabis use has health risks best avoided
by abstaining
• Delay taking up cannabis use until later in life
• Identify and choose lower-risk cannabis products
• Don’t use synthetic cannabinoids
• Avoid smoking
Cannabis for medical purposes
https://policybase.cma.ca/link/policy10045
- Last Reviewed
- 2019-03-03
- Date
- 2010-12-04
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
CMA POLICY
Cannabis for Medical Purposes
CMA Position:
The Canadian Medical Association (CMA) has always recognized the unique requirements of
CMA’s recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-Smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13641
- Date
- 2017-04-07
- Topics
- Health care and patient safety
- Pharmaceuticals, prescribing, cannabis, drugs
purchased. The more
restricted is availability, the easier it is to regulate. The CMA considers prohibiting the
promotion of flavours in vaping products that may appeal to youth, such as soft drinks
and cannabis, to be a positive step.
A recent report published by the World Health Organization and the
CMA’s Recommendations for Bill S-5, an Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other acts
https://policybase.cma.ca/link/policy13918
- Date
- 2018-02-15
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Health care and patient safety
may appeal to youth, such as soft drinks
and cannabis, to be a positive step.
A recent report published by the World Health Organization and the US National Cancer
Institute indicated that websites dedicated to retailing e-cigarettes “contain themes that
may appeal to young people, including
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799
- Date
- 2017-12-07
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
CMA Submission:
Excise Duty Framework for Cannabis Products
Submission to the Government of Canada consultation on
the proposed excise duty framework for cannabis products
December 7, 2017
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017
- Date
- 2018-12-04
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Population health, health equity, public health
?
Training for police and other frontline criminal justice and corrections workers in how to interact with
people with substance use issues is essential. The CMA believes that the government must take a broad
public health policy approach. Changes to the criminal law affecting cannabis must not promote
- Policy Type
- Response to consultation
- Date
- 2018-12-04
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
- Population health, health equity, public health
Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight
https://policybase.cma.ca/link/policy14125
- Date
- 2019-09-03
- Topics
- Health care and patient safety
- Population health, health equity, public health
CMA response:
HEALTH CANADA CONSULTATION ON
POTENTIAL MARKET FOR CANNABIS
HEALTH PRODUCTS THAT WOULD
NOT REQUIRE PRACTITIONER
OVERSIGHT
September 03, 2019
The health risks and harms associated with the use of marijuana
https://policybase.cma.ca/link/policy11138
- Date
- 2014-05-27
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
Medical Association (CMA) is pleased to present this brief to the House of
Commons Standing Committee on Health for consideration as part of its study on the health
risks and harms associated with the use of marijuana.
Marijuana, or cannabis, is a Schedule II drug under the Canadian Controlled Drugs
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954
- Date
- 2016-08-29
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
Risk Cannabis Use Guidelines for
Canadag 27 should be discussed, particularly with teens, in an effort to minimize harm, even if they
choose to continue to use.
It is important that these education programs be designed by governments and health
professionals, and not marijuana producers or
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838
- Date
- 2018-01-19
- Topics
- Pharmaceuticals, prescribing, cannabis, drugs
CMA submission:
PROPOSED APPROACH TO THE
REGULATION OF CANNABIS
Submission to Health Canada
January 19, 2018